Bing Yao, ArriVent CEO
June 30, 2021 10:56 AM EDT
Startups
China

For­mer Viela CEO Bing Yao finds his next gig — bring­ing Chi­nese R&D in­no­va­tion state­side

Nicole DeFeudis

Editor

When Hori­zon Ther­a­peu­tics bought out Viela Bio for $53 a share, every­one won­dered what then-CEO Bing Yao would do next — in­clud­ing him­self. Three months …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times